Outcome Sciences, Inc.
(OUTCOME) announced they will team with the
National Football League
(NFL) to update its Injury Surveillance System, the primary source for injury reporting in the NFL. In addition to providing technology and hosting services for the Injury Surveillance System, Outcome is also providing the NFL and its committees with epidemiological and biostatistical expertise to analyze NFL injury data and support related medical research.
The NFL’s Injury Surveillance System has been in existence since 1980. As part of the collaboration, the NFL training staff will rely on Outcome’s proprietary Outcome System® as the platform for the next generation NFL Injury Surveillance System.
“We are always looking for ways to help athletes at all levels of play stay healthy and safe,” said Dr. Elliott Hershman, Chairman of the NFL Injury and Safety Panel. “We are pleased to be working with Outcome to monitor and analyze injuries as a step towards preventing them.”
“Accurately tracking and analyzing injuries in professional football is the first step towards ultimately reducing their incidence and severity,” said Richard Gliklich, MD, President and CEO of Outcome. “We are pleased to collaborate with the NFL and NFLPA in enhancing the NFL’s Injury Surveillance System and providing ongoing scientific review and research support for a range of initiatives aimed at better understanding football-related injuries and health outcomes.”
The project began with the start of training camp with the participation of five pilot teams, including the New York Giants, New York Jets, Baltimore Ravens, Pittsburgh Steeler,s and the San Francisco 49ers. Following the completion of the pilot phase, the project is expected to be expanded to all of the remaining teams in the NFL. The project also will include the development of additional player studies managed by the NFL Injury and Safety Panel and other NFL medical committees, including the NFL Head, Neck and Spine Medical Committee.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.